<!DOCTYPE html>
<html lang="en">

<head>
	<title>Angelman syndrome</title>
	<meta charset="UTF-8">
	<meta name="format-detection" content="telephone=no">
	<!-- <style>body{opacity: 0;}</style> -->
	<link rel="stylesheet" href="css/style.min.css?_v=20250222115801">
	<link rel="shortcut icon" href="favicon.ico">
	<!-- <meta name="robots" content="noindex, nofollow"> -->
	<meta name="viewport" content="width=device-width, initial-scale=1.0">
</head>

<body>
	<div class="wrapper">
		<header class="header">
			<div class="header__container">
				<div class="header__item">
					<a href="index.html" class="header__logo">
						<img src="img/icons/logo.svg" alt="Image">
					</a>
					<div class="header__navigation navigation">
						<nav class="navigation__body">
							<ul class="navigation__list">
								<li class="navigation__item"><a href="index.html" class="navigation__link">Main</a></li>
								<li class="navigation__item"><a href="about.html" class="navigation__link">About us</a></li>
								<li class="navigation__item"><a href="fields-of-interest.html" class="navigation__link">Fields of interest</a></li>
								<li class="navigation__item"><a href="research-directions.html" class="navigation__link">Research directions</a></li>
								<li class="navigation__item"><a href="foundation.html" class="navigation__link">Foundation</a></li>
							</ul>
						</nav>
					</div>
				</div>
				<div class="header__button">
					<button type="button" class="menu__icon icon-menu"><span></span></button>
				</div>
				<div class="header__menu menu">
					<nav class="menu__body">
						<ul class="menu__list menu__list_1">
							<li class="menu__item_1"><a href="index.html" class="menu__link">Main</a></li>
							<li class="menu__item_1"><a href="about.html" class="menu__link">About us</a></li>
							<li class="menu__item_1">
								<a href="fields-of-interest.html" class="menu__link link-menu">Fields of interest</a>
								<ul class="link-menu__sub-list">
									<li class="link-menu__sub-item"><a href="angelman-syndrome.html" class="link-menu__sub-link">Angelman syndrome</a></li>
									<li class="link-menu__sub-item"><a href="snijders-block.html" class="link-menu__sub-link">Snijders Block-Campeau syndrome</a></li>
									<li class="link-menu__sub-item"><a href="spinal-muscular-atrophy.html" class="link-menu__sub-link">Spinal muscular atrophy</a></li>
									<li class="link-menu__sub-item"><a href="secondary-metabolites.html" class="link-menu__sub-link">Secondary metabolites</a></li>
									<li class="link-menu__sub-item"><a href="personalized-medicine.html" class="link-menu__sub-link">Personalized medicine</a></li>
									<li class="link-menu__sub-item"><a href="customized-gene.html" class="link-menu__sub-link">Autism spectrum disorders</a></li>
								</ul>
							</li>
						</ul>
						<ul class="menu__list menu__list_2">
							<li class="menu__item"><a href="research-directions.html" class="menu__link">Research directions</a></li>
							<li class="menu__item"><a href="foundation.html" class="menu__link">Foundation</a></li>
							<li class="menu__item"><a href="importance.html" class="menu__link">Importance</a></li>
							<li class="menu__item"><a href="contact-us.html" class="menu__link">Contact us</a></li>
							<li class="menu__item"><a href="#" class="menu__link">News</a></li>
							<li class="menu__item"><a href="#" class="menu__link">Events</a></li>
						</ul>
						<div class="menu__action action-menu">
							<div class="action-menu__label">Keep in touch</div>
							<div class="action-menu__body">
								<div class="action-menu__social"><img src="img/icons/01.svg" alt="Image"></div>
								<div class="action-menu__social"><img src="img/icons/02.svg" alt="Image"></div>
								<div class="action-menu__social"><img src="img/icons/03.svg" alt="Image"></div>
							</div>
						</div>
					</nav>
				</div>
			</div>
		</header>
		<main class="page">
			<div class="page__nagivation navigation-menu">
				<div class="navigation-menu__container">
					<ul class="navigation-menu__list">
						<li class="navigation-menu__item"><a href="index.html" class="navigation-menu__link">Main</a></li>
						<li class="navigation-menu__item navigation-menu__item_2"><a href="fields-of-interest.html" class="navigation-menu__link">Fields of
								interest</a></li>
						<li class="navigation-menu__item">
							<a href="angelman-syndrome.html" class="navigation-menu__link"><span>Angelman syndrome</span></a>
						</li>
					</ul>
				</div>
			</div>
			<section class="page__angelman-syndrome angelman-syndrome">
				<div class="angelman-syndrome__container">
					<div class="angelman-syndrome__header">
						<h3 class="angelman-syndrome__title title">Angelman syndrome</h3>
					</div>
					<div class="angelman-syndrome__body body-angelman-syndrome">
						<div class="body-angelman-syndrome__content">
							<h4 class="body-angelman-syndrome__title title">What is AS?</h4>
							<p class="body-angelman-syndrome__text">
								A report describing AS was published in 1965 by a British pediatrician Harry Angelman . AS is a genetic disorder causing
								neurodevelopmental disease with a conserved and recognizable set of symptoms. Most often, AS is characterized with serious
								intellectual disability (complete lack of speech and decreased cognitive performance), happy demeanor with easily provoked
								laughter, movement and balance disorders (ataxia). Among common symptoms are seizures, that start in early childhood; notably,
								AS shows a characteristic electroencephalographic pattern. Finally, children with AS have sleeping disorders and disrupted
								circadian rhythm. Less often symptoms include microcephaly and body dysmorphia, gastrointestinal tract disorders, and
								hypopigmentation [2]. Features, resembling autistic-spectrum disorders, could be observed in people with AS. <br> Although AS
								is
								considered rare, it’s prevalence is about 1/10,000-1/20,000. AS could be recognized at 6-12 months’ age, when babies start to
								exhibit lack of usual motor activities, like crawling. Hence, it is important to undergo genetic testing as soon as parents
								suspect AS: although the definitive cure is (so far) absent, different therapeutic approaches are available to increase the
								quality of life and mitigate symptoms
							</p>
						</div>
						<div class="body-angelman-syndrome__image">
							<picture><source srcset="img/angelman-syndrome/what-is-as/01.webp" type="image/webp"><img src="img/angelman-syndrome/what-is-as/01.png" alt="Image"></picture>
						</div>
					</div>
				</div>
			</section>
			<section class="page__what-as what-as">
				<div class="what-are-molecular">
					<div class="what-are-molecular__container">
						<div class="what-are-molecular__header">
							<h3 class="what-are-molecular__title title">What are molecular causes of AS?</h3>
						</div>
						<div class="what-are-molecular__content">
							<p class="what-are-molecular__text what-are-molecular__text_1">
								Mutation interfering with the expression of UBE3A gene, coding for ubiquitin protein ligase E3A, lead to the AS [4, 5]. In
								humans, the UBE3A gene is subject to genomic imprinting, a process that results in the gene being expressed in a
								parent-of-origin
								specific manner. For the region of chromosome 15 that includes UBE3A (15q11-q13), only the maternal copy of the gene is
								usually
								active in certain areas of the brain, while the paternal copy is typically silenced by a process involving DNA methylation and
								the imprinting center [6–8].
							</p>
							<p class="what-are-molecular__text what-are-molecular__text_2">
								The silencing of the paternal UBE3A allele is controlled by an imprinting control region located upstream of the SNURF-SNRPN
								gene, within the same 15q11-q13 region. This region includes the Prader-Willi syndrome/Angelman syndrome (PWS/AS) imprinting
								center. The paternal allele of the imprinting center is methylated, a chemical modification of DNA that does not change the
								DNA
								sequence but affects gene expression. Methylation of the ICR on the paternal chromosome prevents the binding of transcription
								factors necessary for the expression of UBE3A, leading to its silencing. The silencing mechanism also involves the
								transcription
								of an antisense RNA from the SNURF-SNRPN locus on the paternal allele, which spans the UBE3A gene. This antisense RNA, UBE3A
								antisense transcript (UBE3A-ATS or SNHG14), is thought to interfere with the transcription of the paternal UBE3A allele. The
								exact mechanism by which UBE3A-ATS silences UBE3A is still under investigation, but it is believed that the transcript might
								block the progression of RNA polymerase during the transcription of UBE3A, prevent the proper splicing of UBE3A pre-mRNA, or
								recruit chromatin-modifying enzymes that repress transcription. The methylation of DNA and the action of antisense RNA are
								associated with changes in chromatin structure that further reinforce the silencing of UBE3A on the paternal allele. Histone
								modifications, such as deacetylation and methylation, lead to a more condensed chromatin state, making the DNA less accessible
								for transcription.
							</p>
						</div>
						<div class="what-are-molecular__image">
							<picture><source srcset="img/angelman-syndrome/what-are-molecular/01.webp" type="image/webp"><img src="img/angelman-syndrome/what-are-molecular/01.png" alt="Image"></picture>
						</div>
					</div>
				</div>
				<div class="as-can-result">
					<div class="as-can-result__container">
						<div class="as-can-result__header">
							<h3 class="as-can-result__title">
								AS can result from several genetic mutations, all of which lead to a lack or loss of function of the maternal UBE3A allele:
							</h3>
						</div>
						<div class="as-can-result__body body-as-can-result">
							<div class="body-as-can-result__content">
								<div class="body-as-can-result__item body-as-can-result__item_1">
									<div class="body-as-can-result__value">1</div>
									<p class="body-as-can-result__text">Deletion of the maternal copy of chromosome 15q11-q13. This is the most common cause,
										accounting for about 70% of cases. The deletion removes the active UBE3A gene along with neighboring genes, leading to
										the syndrome.</p>
								</div>
								<div class="body-as-can-result__item body-as-can-result__item_2">
									<div class="body-as-can-result__value">2</div>
									<p class="body-as-can-result__text">Mutation of the maternal UBE3A gene. In about 11% of cases, a mutation within the UBE3A
										gene itself prevents the production of functional UBE3A protein from the maternal allele.</p>
								</div>
								<div class="body-as-can-result__item body-as-can-result__item_3">
									<div class="body-as-can-result__value">3</div>
									<p class="body-as-can-result__text">Paternal uniparental disomy (UPD). A rare cause where the child inherits two copies of
										chromosome 15 from the father and none from the mother. Since the paternal UBE3A gene is normally silenced in the brain,
										this results in no active UBE3A gene expression in the child’s brain.</p>
								</div>
								<div class="body-as-can-result__item body-as-can-result__item_4">
									<div class="body-as-can-result__value">4</div>
									<p class="body-as-can-result__text">Imprinting defect. Also rare, this involves a failure in the process that normally
										silences the paternal copy of UBE3A in the brain, without a deletion or mutation in the gene itself. This can be due to
										deletions or mutations in the imprinting center. <br> The UBE3A gene encodes an E3 ubiquitin ligase that tags defective
										proteins for degradation. The absence or insufficiency of this enzyme in the brain disrupts the normal turnover of
										proteins, affecting neuronal function and development, and leading to the symptoms of Angelman Syndrome.</p>
								</div>
							</div>
							<div class="body-as-can-result__image">
								<picture><source srcset="img/angelman-syndrome/as-can-result/01.webp" type="image/webp"><img src="img/angelman-syndrome/as-can-result/01.jpg" alt="Image"></picture>
							</div>
						</div>
					</div>
				</div>
			</section>
			<section class="page__gene gene">
				<div class="gene__container">
					<div class="gene__header header-gene">
						<h3 class="header-gene__title title">Gene therapy solutions for AS treatment and management</h3>
						<p class="header-gene__text">
							Currently, there are two main approaches to modify the phenotype of AS by modulating gene expression:
							independent expression of a functional copy of UBE3A and unsilencing of the paternal copy of UBE3A using antisense
							oligonucleotides (ASOs).15:33
						</p>
					</div>
					<div class="gene__body body-gene">
						<div class="body-gene__item body-gene__item_1">
							<div class="body-gene__image body-gene__image_1">
								<picture><source srcset="img/angelman-syndrome/gene/01.webp" type="image/webp"><img src="img/angelman-syndrome/gene/01.jpg" alt="Image"></picture>
							</div>
							<div class="body-gene__content">
								<div class="body-gene__value">1.</div>
								<p class="body-gene__text body-gene__text_1">
									I) Independent expression of a functional copy of UBE3A is a viable approach, since the coding RNA spans for only ca. 2,600
									bp, being an optimal size for AAV vector capacity. Several reports describe expression of UBE3A using the strong
									constitutive promoter and AAV vector, that mitigated AS-symptoms in model mice [9]. An alternative approach included the
									isolation of hematopoietic stem and progenitor cells (HSPC). HSPCs were then introduced into culture and transfected with a
									lentiviral vector expressing UBE3A. After, the modified HSPC were engrafted to mice and successfully colonized the bone
									marrow. Further, microglial cells, derived from these HSPC would migrate to brain, starting to express UBE3A giving
									therapeutic effect. Described approach allowed to successfully restore AS-like phenotype. This approach has such advantages
									as the most long-term and stable expression platform. <br>
									In addition, CRISPR-Cas9 and CRISPR-Cas13 genome and transcriptome editing approaches were successfully tested and
									partially restored AS-associated phenotypes in murine models, holding promise for further clinical application.
								</p>
								<p class="body-gene__text body-gene__text_2">
									I) Independent expression of a functional copy of UBE3A is a viable approach, since the coding RNA spans for only ca. 2,600
									bp, being an optimal size for AAV vector capacity. Several reports describe expression of UBE3A using the strong
									constitutive promoter and AAV vector, that mitigated AS-symptoms in model mice [9]. An alternative approach included the
									isolation of hematopoietic stem and progenitor cells (HSPC). HSPCs were then introduced into culture and transfected with a
									lentiviral vector expressing UBE3A. After, the modified HSPC were engrafted to mice and successfully colonized the bone
									marrow. Further, microglial cells, derived from these HSPC would migrate to brain, starting to express UBE3A giving
									therapeutic effect. Described approach allowed to successfully restore AS-like phenotype. This approach has such advantages
									as the most long-term and stable expression platform
								</p>
							</div>
						</div>
						<div class="body-gene__item body-gene__item_2">
							<div class="body-gene__content">
								<div class="body-gene__value">2.</div>
								<p class="body-gene__text">
									As double-stranded RNA molecules are not normal for the cell and get digested with ribonuclease H, application of ASOs,
									complementary to the UBE3A-ATS, is a viable way to decrease the pool of the antisense RNA, and thus activate the expression
									of UBE3A paternal copy. Application of ASOs led to increase of UBE3A expression in cortex, cerebellum, and hippocampus of
									model-mice [11]. Treatment reversed memory-related abnormalities, although motor dysfunction was not reversed. In fact,
									application of ASO to treat and manage AS was approved for clinical trials by FDA.
								</p>
							</div>
							<div class="body-gene__image body-gene__image_2">
								<picture><source srcset="img/angelman-syndrome/gene/02.webp" type="image/webp"><img src="img/angelman-syndrome/gene/02.jpg" alt="Image"></picture>
							</div>
						</div>
					</div>
				</div>
			</section>
			<section class="page__drug drug">
				<div class="drug__container">
					<div class="drug__content">
						<div class="drug__body">
							<h3 class="drug__title">Drug treatment solutions for AS treatment</h3>
							<p class="drug__text">A promising way to unsilenced paternal copy of UBE3A are topoisomerase I inhibitors – either naturally
								occurring or semisynthetic compounds of plant (mostly) origin, that are usually used for cancer treatment. One of those – FDA
								approved anticancer compound topothecan – efficiently inhibited TOP1 (brain-expressed topoisomerase), leading to the
								un-silencing
								of paternal derived UBE3A allele. Investigation of molecular mechanism of topotecan action in vitro allowed to assume that the
								latter does not change the methylation pattern or the activity of imprinting center, but reduced the level of anti-sense
								transcript expressed from a paternal-derived UBE3A allele. In vivo, topotecan was administrated by infusion into brain
								hemisphere
								or intratecal, giving a dose-dependent activation of paternal copy of UBE3A allele. The expression lasted even 12 weeks after
								the
								elimination of topotecan, giving hope for a lasting effec</p>
						</div>
					</div>
					<div class="drug__image animation-pulse">
						<picture><source srcset="img/angelman-syndrome/drug/01.webp" type="image/webp"><img src="img/angelman-syndrome/drug/01.png" alt="Image"></picture>
					</div>
				</div>
			</section>
		</main>
		<footer class="footer">
			<div class="footer__container">
				<div class="footer__body">
					<div class="footer__logo">
						<a href="index.html"><img src="img/icons/logo.svg" alt="Image"></a>
					</div>
					<ul class="footer__list footer__list_1">
						<li class="footer__item_1"><a href="index.html" class="footer__link">Main</a></li>
						<li class="footer__item_1"><a href="about.html" class="footer__link">About us</a></li>
						<li class="footer__item_1"><a href="importance.html" class="footer__link">Importance</a></li>
						<li class="footer__item_1"><a href="education.html" class="footer__link">Education</a></li>
						<li class="footer__item_1"><a href="research-directions.html" class="footer__link">Research directions</a></li>
						<li class="footer__item_1"><a href="foundation.html" class="footer__link">Foundation</a></li>
						<li class="footer__item_1"><a href="#" class="footer__link">News</a></li>
						<li class="footer__item_1"><a href="#" class="footer__link">Events</a></li>
						<li class="footer__item_1"><a href="contact-us.html" class="footer__link">Contact us</a></li>
					</ul>
					<ul class="footer__list footer__list_2">
						<li class="footer__item_2"><a href="fields-of-interest.html" class="footer__link">Fields of interest</a></li>
						<li class="footer__item_2"><a href="angelman-syndrome.html" class="footer__link">Angelman syndrome</a></li>
						<li class="footer__item_2"><a href="snijders-block.html" class="footer__link">Snijders Block-Campeau syndrome</a></li>
						<li class="footer__item_2"><a href="spinal-muscular-atrophy.html" class="footer__link">Spinal muscular atrophy</a></li>
						<li class="footer__item_2"><a href="secondary-metabolites.html" class="footer__link">Secondary metabolites</a></li>
						<li class="footer__item_2"><a href="#" class="footer__link">Antimicrobials</a></li>
						<li class="footer__item_2"><a href="personalized-medicine.html" class="footer__link">Personalized medicine</a></li>
						<li class="footer__item_2"><a href="customized-gene.html" class="footer__link">Autism spectrum disorders</a></li>
					</ul>
					<div class="footer__action action-footer">
						<div class="action-footer__label">Keep in touch</div>
						<div class="action-footer__body">
							<a href="#" class="action-footer__social"><img src="img/icons/01.svg" alt="Image"></a>
							<a href="#" class="action-footer__social"><img src="img/icons/02.svg" alt="Image"></a>
							<a href="#" class="action-footer__social"><img src="img/icons/03.svg" alt="Image"></a>
						</div>
					</div>
				</div>
			</div>
		</footer>
		<button type="button" class="scrollup"></button>
	</div>
	<script src="js/app.min.js?_v=20250222115801"></script>
</body>

</html>